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Diamond-Blackfan anemia (DBA) is a rare congenital red cell aplasia associated with mutations in ribosomal proteins (RP) in 49-71% of cases. 1 DBA is a clinically heterogeneous disorder with one-third of patients developing transfusion-acquired iron overload. 2 The severity of anemia and transfusion dependency in DBA is comparable to transfusiondependent beta-thalassemia major; however, moderate to severe suppression of erythropoiesis in DBA 2 is in contrast to accelerated ineffective erythropoiesis in beta-thalassemia. 3, 4 The knowledge of systemic iron regulation in DBA is limited.
In this study, we assessed selected markers of erythropoietic activity and iron metabolism including the key molecule of this process, hepcidin, in DBA patients from the Czech National DBA Registry (Table 1, Supplementary Table S1 ). 5 The cohort consisted of twelve patients receiving regular transfusions with or without chelation therapy, four patients on steroids, seven patients in remission without treatment, and two patients treated with corticosteroids and occasional transfusions. Nine patients, mostly from the transfusiondependent group, were concomitantly treated with leucine (Supplementary Table S1 ). 6 In transfusion-dependent patients, reduced number of erythroblasts in the bone marrow (median 0.8%) together with markedly decreased soluble transferrin receptor (sTfR, often under the lower limit of detection), confirmed severely suppressed erythropoiesis which corresponded to substantially elevated erythropoietin (EPO) levels (median 2452 IU/L) ( Table   1 ). Analysis of iron parameters showed increased serum iron, transferrin saturation (TSAT) and high ferritin levels (median 1290 ng/mL) ( Table 1 ). This suggests that erythropoiesis of these patients is not able to utilize transferrin-bound iron effectively. Consistently, liver biopsy in five selected transfusion-dependent patients revealed markedly elevated liver iron concentration (LIC) ( Table 1) . Moreover, massive iron stores were detected in both hepatocytes and Kupffer cells ( Figure 1A ), distinguishing DBA from beta-thalassemia major with iron deposits predominantly in macrophages. 4 The macrophage iron loading can be attributed to non-effective erythrocyte-derived iron recycling. 7, 8 Iron deposits in hepatocytes likely resulted from increased iron uptake by these cells; the involvement of non-transferrinbound iron (NTBI) needs to be considered as NTBI can be found in the plasma of patients with oversaturated transferrin and liver is the primary site for deposition of free iron from plasma. 9, 10 Since 2009, all our transfusion-dependent patients have been monitored for potential cardiac, liver and pancreatic iron overload by magnetic resonance imaging (MRI).
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Contrary to transfusion-dependent DBA patients, patients who are currently in disease remission or treated with steroids showed improved erythropoiesis as documented by near normal/higher number of bone marrow erythroblasts and the levels of sTfR within the normal 3 range (Table 1) . These patients had slightly increased or even normal levels of ferritin and near normal serum iron and TSAT ( Figure 1B ). When hepcidin was assessed in individual subgroups of DBA patients, patients on regular transfusions showed significantly elevated hepcidin (median 341.5 pg/mL), as it was previously shown for transfusion-dependent beta-thalassemia major patients. 4 Increased hepcidin above the median value of controls was detected even in the youngest patients being 1.0 and 2.7 years old (6-times and 20-times, respectively). This suggests that the absent or diminished erythropoiesis in the bone marrow together with transfusions is the driving factor for iron overload since early childhood. In contrast, DBA patients in remission or treated with steroids had hepcidin levels comparable to controls (medians 72.1 and 24.7 pg/mL, respectively) ( Figure 1B ). As erythropoiesis is known to produce a signal for hepcidin suppression, 7, 8 DBA patients with restored erythropoietic activity are likely to be able to attenuate hepcidin expression and thus increase the iron pool available for improved erythropoiesis. In agreement with this concept, we detected a trend towards lower hepcidin-ferritin ratio in steroids-receiving patients (median 0.151) or patients in remission (median 0.222) when compared to transfusion-dependent patients (median 0.240) (Table 1) , although these individual values were not significantly different from hepcidinferritin ratio of healthy controls (median 0.35). 12 Indeed, the hepcidin-ferritin ratio which indicates suppression of hepcidin proportional to iron loading, is much higher in transfused DBA patients (range 0.09-1.35) than hepcidin-ferritin ratio reported for transfusion-dependent beta-thalasemia major patients (range 0.02-0.3), 4 suggesting that the erythroid drive suppressing hepcidin is much stronger in beta-thalassemia and not completely attenuated by transfusions. On the other hand, the bone marrow of DBA patients receiving transfusions is probably not releasing the putative erythroid suppressor of hepcidin production.
In the two patients evaluated independently, hepcidin-ferritin ratio was more comparable with steroids-receiving patients, reflecting their improved erythropoiesis (Table 1) . Nevertheless, patient CZUH37 inherited a homozygous C282Y HFE mutation (Supplementary Table S2 ),
Hepcidin levels in Diamond-Blackfan anemia 4 which may contribute to inappropriately low levels of hepcidin (173.9 ng/mL) for the observed hyperferritinemia (3150 ng/mL). 13 We next examined the levels of growth differentiation factor 15 (GDF15), a candidate negative regulator of hepcidin in beta-thalassemia and a marker of ineffective erythropoiesis. 3 Significantly increased levels of GDF15 were detected for the whole DBA cohort as well as for the differently treated groups when compared to normal controls ( Figure 1C ). We suppose that elevated levels of GDF15 in DBA patients may reflect increased apoptosis of bone marrow erythroblasts that we observed in DBA patients selected for the TUNEL assay (Supplementary Figure S1) . 3 Lastly, we assessed which of the aforementioned signals/markers contribute to the regulation of hepcidin synthesis in DBA. Hepcidin positively correlated with ferritin (P=0.00003, Figure   1D ), reflecting hepcidin stimulation by the patients' iron overload. An inverse correlation between the percentage of bone marrow erythroblasts and hepcidin levels (P=0.000003, Figure 1E ) is consistent with negative regulation of hepcidin synthesis by erythropoietic activity. Although a negative correlation between EPO and the number of erythroblasts in the bone marrow (not shown) confirms that EPO is stimulated in response to suppressed erythropoiesis and hypoxia, a positive correlation between hepcidin and EPO (P=0.001, Figure 1F ) demonstrates that hepcidin suppression by EPO requires active erythropoiesis in the bone marrow. 14,15 Similarly, no correlation between hepcidin or hepcidin-ferritin ratio and GDF15 indicates that GDF15 is not playing a hepcidin-regulatory role in DBA.
We conclude that DBA patients with different severity of anemia and different treatment strategies have diverse levels of hepcidin and iron overload. Hepcidin production in DBA reflects variable erythropoietic activity in the bone marrow and further contributes to the heterogeneity of this disease. It will be important to address if some of these dissimilarities can be attributed to a different type of disease-causing RP mutations.
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Supplemental Material and Methods

Patients
The DBA cohort consists of twenty-five patients (eleven males and fourteen females) from the Czech National DBA Registry at the age of 1.0-42.9 years (median 23.7 years) with different clinical severity. Most of the patients have been previously described; 1 the group also includes five newly diagnosed patients. The causative RP mutation (RPS7, RPS17, RPS19, RPS26, RPL5 and RPL 11, respectively) was found in twenty patients; five patients are negative for all known RP mutations. Detailed characteristics of the patients are shown in Supplementary Table 1 .
The study and the informed consent as per the Declaration of Helsinki were approved by the Ethics Committee of Palacky University Hospital, Olomouc, Czech Republic. A cohort of 12 children examined prior to planned minor surgery (inguinal or umbilical hernia, plastic surgery) and 5 young healthy adults served as controls for hepcidin levels interpretation; the normal range for GDF15 was determined in a group of four children and four adults. 
Hematological and biochemical analysis
Blood was taken during routinely performed venous puncture; for transfusion-dependent patients pre-transfusion samples were collected. Blood counts were examined on Sysmex XE-500 analyzer (Sysmex). Biochemical serum parameters of iron metabolism and inflammation:
serum iron (Fe), total iron binding capacity (TIBC), transferrin saturation (TSAT), soluble transferrin receptor (sTfR) and CRP levels were determined with standard methods. The patients' serum erythropoietin (EPO) concentrations were measured by a solid-phase chemiluminescent immunochemical reaction. 1 Bone marrow samples were used for cytological and histopathological examination and immunohistochemistry. Liver biopsies were subjected to histopathological examination, determination of liver iron concentration (LIC, mg/g dry weight) and Perl's Prussian blue staining for non-heme iron.
Hepcidin analysis
The serum hepcidin levels were measured by reverse-phase liquid chromatography using the UltiMate 3000 Nano LC System (Thermo Fisher Scientific, Sunnyvale, CA, USA) coupled to the QTRAP 5500 mass spectrometer (AB SCIEX, Framingham, MA, USA) as we previously described.
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GDF15 measurements
The serum levels of growth differentiation factor 15 (GDF15) were quantified according to the manufacturer's instructions using the Human GDF-15 Quantikine ELISA Kit (R&D Systems, Inc., Minneapolis, MN, USA).
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Immunohistochemistry
Bone marrow biopsy samples were fixed in neutral-buffered formalin for 24 hours and embedded into paraffin. Immunohistochemical staining was performed as previously described. 3 Glycophorin A staining (H-60, 1:250; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was followed by analysis of apoptosis using the alkaline phosphatase (AP) In Situ Cell
Death Detection Kit (Roche Applied Science, Mannheim, Germany) according to the manufacturer's instructions. The slides were analyzed with an Olympus BX 51 light microscope (Olympus, Hamburg, Germany).
HFE mutational analysis
The sequence analysis of the two most common HFE variants (p.C282Y and p.H63D) in exons 4 and 2 (accession: NM_000410.3) was performed as previously described.
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Statistical methods
All statistical analyses were done using the Statistica 10 software (StatSoft, Inc. 
